Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32687619 | 0.92 | NR1H2 (0.47) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL343699 | 0.92 | NR1H2 (0.47) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL7260840 | 0.92 | NR1H2 (0.47) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL1490070 | 0.90 | GPR119 (0.54) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL7417693 | 0.89 | GPR119 (0.55) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL5341727 | 0.88 | HPGD (0.54) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL735207 | 0.88 | HPGD (0.54) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL26655119 | 0.86 | GPR119 (0.48) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL447042 | 0.86 | HPGD (0.55) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL15085741 | 0.86 | GPR119 (0.59) | HPGDKDM4EPKMGPR119RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4482527-B1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20260001875-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREATMENT OF PARKINSON'S DISEASE | UNIV DUNDEE (GB) | 2026-01-01 | — | — | US | disclosed |
| US-20250154288-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-05-15 | — | — | US | disclosed |
| EP-4522603-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREAMENT OF PARKINSON'S DISEASE | University Of Dundee (GB) | 2025-03-19 | — | — | EP | disclosed |
| WO-2025046523-A1 | NOVEL PYRIDO PYRIDAZINONE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 삼진제약주식회사 | 2025-03-06 | — | — | WO | disclosed |
| CN-119325470-A | Aminopyrimidinyl derivatives for the treatment of parkinson's disease | 邓迪大学 | 2025-01-17 | — | — | CN | disclosed |
| EP-4482527-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-01-01 | — | — | EP | disclosed |
| CN-119136836-A | Cytotoxic targeting chimeras for C-C chemokine receptor 2 expressing cells | 葛兰素史克知识产权发展有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-117883449-A | ENPP1 inhibitors and their use for the treatment of cancer | 里兰斯坦福初级大学理事会 | 2024-04-16 | — | — | CN | disclosed |
| EP-4327882-A2 | ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-02-28 | — | — | EP | disclosed |
| US-5281585-A | Secondary amide containing antagonist | MERCK & CO., INC. (US) | 1994-01-25 | — | — | US | disclosed |
| US-5272158-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1993-12-21 | — | — | US | disclosed |
| EP-0540334-A1 | Fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1993-05-05 | — | — | EP | disclosed |
| CN-1067883-A | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1993-01-13 | — | — | CN | disclosed |
| WO-1992019595-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1992-11-12 | — | — | WO | disclosed |
| EP-0512829-A1 | Fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1992-11-11 | — | — | EP | disclosed |
| EP-0512831-A1 | Fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1992-11-11 | — | — | EP | disclosed |
| EP-0094766-B1 | QUINAZOLINE CARDIAC STIMULANTS | Pfizer Limited (GB) | 1986-12-30 | — | — | EP | disclosed |
| US-4489075-A | Cyclic sulfonamidoalkyl substituted 4-piperidinoquinazoline cardiac stimulants | PFIZER INC. (US) | 1984-12-18 | — | — | US | disclosed |
| EP-0094766-A2 | Quinazoline cardiac stimulants | Pfizer Limited (GB) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154288-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | CCR2, CCRL2, CCR5 | HPGD 4542/4885KDM4E 4774/4885PKM 4871/4885 |
| US-20260001875-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREATMENT OF PARKINSON'S DISEASE | LRRK2, XIAP, PARK7 | HPGD 4483/4885KDM4E 1120/4885PKM 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.